26 Osteogenesis Imperfecta Clinical Trials in Portland, OR (2026)

Q: How do I join a clinical trial in Portland?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Portland research site will contact you.

Recruiting Osteogenesis Imperfecta Studies in Portland

NCT03511118Recruiting

Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

Over half of women in the US who are breastfeeding their infants take prescription drugs. You are being asked to participate in this study because you are breastfeeding your infant and are currently t...

Portland, OR1,600 participantsDuke University

View Study Details

NCT02432625Recruiting

BBD Longitudinal Study of Osteogenesis Imperfecta

Osteogenesis Imperfecta (OI) is a rare disorder of increased bone fragility characterized by fractures with minimal or absent trauma, dentinogenesis imperfecta (DI), and, in adult years, hearing loss....

Portland, OR1,000 participantsBaylor College of Medicine

View Study Details

NCT07690436Recruiting

Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CM

This multicenter pilot study will enroll adult participants with a confirmed clinical diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) and heart failure (HF) controls with documentation wit...

Portland, OR500 participantsAstraZeneca

View Study Details

NCT06940674Recruiting

Adjunctive Cannabidiol for Recovery From Opioid Study

The long-term goal of the project is to determine whether cannabidiol (CBD) can reduce craving and relapse in individuals with opioid use disorder (OUD). The first phase of this project was an open cr...

Portland, ORPHASE3450 participantsIcahn School of Medicine at Mount Sinai

View Study Details

NCT07332182Recruiting

MaioRegen Prime Study for the Treatment of Deep Osteochondral Lesion of the Knee

The present study aims to compare the efficacy and the safety of MaioRegen Prime to Debridement (SSOC) in patients with deep osteochondral lesions of the knee joint. The foreseen population involves p...

Portland, ORNA400 participantsFin-Ceramica Faenza Spa

View Study Details

NCT05304377Recruiting

A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia

The purpose of this study is to evaluate the safety, tolerability and determine the recommended dose for further clinical evaluation of ELVN-001 in patients with chronic myeloid leukemia with and with...

Portland, ORPHASE1250 participantsEnliven Therapeutics

View Study Details

NCT07169409Recruiting

Right Tools, Right Time, Right Place: Telehealth for Opioid Use Disorder in Vulnerable Settings

Our primary objective is to evaluate the ability of Boulder Care's telehealth-platform to create the necessary paradigmatic shift in Opioid Use Disorder (OUD) treatment to reach vulnerable populations...

Portland, ORPHASE1250 participantsBoulder Care

View Study Details

NCT06008795Recruiting

BLOCK-SAH - PPF-Block for Post-SAH Headache

BLOCK-SAH is a phase II, multicenter, randomized, double-blinded, placebo-controlled clinical trial with a sequential parallel comparison design (SPCD) of bilateral pterygopalatine fossa (PPF) injecti...

Portland, ORPHASE2195 participantsUniversity of Florida

View Study Details

NCT05758493Recruiting

Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis

This is a single center prospective study evaluating 124I-evuzumitide in patients with systemic amyloidosis. The purpose of this study is to 1) Establish the diagnostic accuracy of 124I-evuzumitide in...

Portland, ORPHASE2150 participantsOregon Health and Science University

View Study Details

NCT07228273Recruiting

Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia

This phase II trial compares induction and consolidation therapy with fludarabine, cytarabine, idarubicin, and venetoclax to cytarabine and daunorubicin induction and cytarabine consolidation for the ...

Portland, ORPHASE2102 participantsOHSU Knight Cancer Institute

View Study Details

NCT06562777Recruiting

Observational Study of Sex Differences in Symptoms During Immune Checkpoint Inhibitor Treatment for People With Cancer

This study aims to learn more about symptoms that patients experience while receiving immunotherapy for cancer....

Portland, OR100 participantsOHSU Knight Cancer Institute

View Study Details

NCT07412704Recruiting

A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and the preliminary evidence of disease-modifying effect of BMS-986528 in participants ...

Portland, ORPHASE184 participantsBristol-Myers Squibb

View Study Details

NCT07216443Recruiting

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

This study will evaluate the safety, tolerability, and efficacy of Orca-T in participants undergoing reduced intensity or non-myeloablative allogeneic hematopoietic cell transplantation (alloHCT) for ...

Portland, ORPHASE280 participantsOrca Biosystems, Inc.

View Study Details

NCT07062588Recruiting

Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN)

This study will determine the effect of treatment of AGA2115 in adults with Type I, III, or IV osteogenesis imperfecta versus placebo....

Portland, ORPHASE280 participantsAngitia Incorporated Limited

View Study Details

NCT06158854Recruiting

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion

Immunoglobulin light chain (AL) amyloidosis is the most common form of systemic amyloidosis. AL amyloidosis has many root causes and is characterized by the overproduction of AL that are secreted by c...

Portland, ORPHASE176 participantsAbbVie

View Study Details

NCT06342453Recruiting

CREATE: Art for Children With Cancer

This clinical trial is being done to develop and test how well creative arts interventions (drawing, painting, making sculptures) compared to watching videos can affect symptoms and impact the quality...

Portland, ORNA72 participantsOHSU Knight Cancer Institute

View Study Details

NCT06805825Recruiting

A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

This open-label clinical trial will evaluate the safety and tolerability of NN3201 in subjects with advanced and/or metastatic solid tumors known to express c-Kit....

Portland, ORPHASE167 participantsNovelty Nobility, Inc.

View Study Details

NCT03874052Recruiting

Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

This phase I trial studies the side effects and best dose of ruxolitinib when given together with venetoclax and compares the effect of ruxolitinib in combination with venetoclax to venetoclax and aza...

Portland, ORPHASE151 participantsJennifer Saultz

View Study Details

NCT06533098Recruiting

A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

The purpose of this study is to assess the efficacy and safety of nipocalimab in reducing the risk of severe fetal and neonatal alloimmune thrombocytopenia (FNAIT)....

Portland, ORPHASE350 participantsJanssen Research & Development, LLC

View Study Details

NCT06201416Recruiting

Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis

This study will test the safety and effects of SBT777101 when given as a single dose to subjects with rheumatoid arthritis. It is the first study of this treatment being done in humans. Increasing dos...

Portland, ORPHASE148 participantsSonoma Biotherapeutics, Inc.

View Study Details

NCT07548983Recruiting

Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation

This phase I trial studies the side effects and best dose of ruxolitinib (Rux) therapy alone (monotherapy) followed by Rux plus azacitidine (AZA) maintenance therapy and to see how well it works in tr...

Portland, ORPHASE140 participantsOHSU Knight Cancer Institute

View Study Details

NCT04659616Recruiting

Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia

This phase I trial identifies the best dose and clinical benefit of giving pemigatinib following standard induction chemotherapy in patients with newly diagnosed acute myeloid leukemia. Pemigatinib se...

Portland, ORPHASE132 participantsOHSU Knight Cancer Institute

View Study Details

NCT06357182Recruiting

Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia

This phase I trial tests the safety, side effects, and best dose of iadademstat when given together with azacitidine and venetoclax in treating patients with newly diagnosed acute myeloid leukemia (AM...

Portland, ORPHASE130 participantsOHSU Knight Cancer Institute

View Study Details

NCT05003310Recruiting

ConsideRAte Study - Splenic Stimulation for RA

This study will evaluate the safety, tolerability, and effects of stimulating the splenic neurovascular bundle (NVB) with the Galvani System, which consists of a lead, implantable pulse generator, ext...

Portland, ORNA28 participantsGalvani Bioelectronics

View Study Details

NCT06895473Recruiting

Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome

This phase II trial tests how well cytarabine (Ara-C), methotrexate, and hydrocortisone given between the spinal cord and the membranes that protect it (intrathecal \[IT\]) works in preventing high-gr...

Portland, ORPHASE226 participantsOHSU Knight Cancer Institute

View Study Details

NCT07844694Recruiting

Low-Dose Sirolimus for the Treatment of RUNX1 Familial Platelet Disorder

This phase I trial studies the safety and side effects of low-dose sirolimus in treating patients with RUNX1 familial platelet disorder (FPD). RUNX1-FPD is a rare inherited disorder with symptoms such...

Portland, ORPHASE16 participantsOHSU Knight Cancer Institute

View Study Details

About Osteogenesis Imperfecta Clinical Trials in Portland

Osteogenesis imperfecta is a group of genetic disorders mainly affecting the bones, causing them to break easily, often from little or no apparent cause. It is caused by defects in collagen production. Treatment includes bisphosphonates, physical therapy, and surgical rodding.

There are currently 26 osteogenesis imperfecta clinical trials recruiting participants in Portland, OR. These studies are seeking a combined 5,767 participants. Research is being sponsored by Duke University, Baylor College of Medicine, AstraZeneca and 16 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Osteogenesis Imperfecta Clinical Trials in Portland — FAQ

Are there osteogenesis imperfecta clinical trials in Portland?

Yes, there are 26 osteogenesis imperfecta clinical trials currently recruiting in Portland, OR. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Portland?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Portland research site will contact you about next steps.

Are clinical trials in Portland free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Portland studies also compensate for your time and travel.

What osteogenesis imperfecta treatments are being tested?

The 26 active trials in Portland are testing new therapies including novel drugs, biologics, and treatment approaches for osteogenesis imperfecta.

Data updated October 22, 2026 from ClinicalTrials.gov